Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.
Brian Leyland-Jones, MBBS, PhD
Advertisement
Articles by Brian Leyland-Jones, MBBS, PhD
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing
Advertisement
Latest Updated Articles
Dr. Leyland-Jones Discusses Genome SequencingFebruary 20th 2012
Dr. Leyland-Jones on Breast Cancer Risk Assessment ToolsMarch 3rd 2014
Dr. Leyland-Jones Discusses the Phase III HERA TrialDecember 7th 2012
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5